首页 | 本学科首页   官方微博 | 高级检索  
检索        

经导管主动脉瓣置换术的现状与发展趋势
引用本文:贺毅,周海婷,朱书强,吴永兵.经导管主动脉瓣置换术的现状与发展趋势[J].中南大学学报(医学版),2017,42(8):991-996.
作者姓名:贺毅  周海婷  朱书强  吴永兵
作者单位:南昌大学 1. 第二临床医学院;2. 第二附属医院心脏大血管外科,南昌 330006
摘    要:目前,尽管严重主动脉狭窄的治疗指南仍以外科手术置换(surgical aortic valve replacement,SAVR)为治疗标 准,但随着大血管外科技术的不断发展,经导管主动脉瓣置换术(transcatheter aortic valve implantation,TAVI)逐渐成为 高危和禁忌SAVR患者的常规治疗措施。近年来各瓣膜厂商,包括国内医药公司,对瓣膜技术极力地推进,使得TAVI 技术取得了显著成效,加上其并发症也得到了有效控制,TAVI有望在治疗主动脉狭窄乃至关闭不全上取代传统术 式,应用前景可观。

关 键 词:主动脉狭窄  经导管主动脉瓣置换术  外科主动脉瓣置换术  

Transcatheter aortic valve implantation: Present and development trend
HE Yi,ZHOU Haiting,ZHU Shuqiang,WU Yongbing.Transcatheter aortic valve implantation: Present and development trend[J].Journal of Central South University (Medical Sciences)Journal of Central South University (Medical Sciences),2017,42(8):991-996.
Authors:HE Yi  ZHOU Haiting  ZHU Shuqiang  WU Yongbing
Institution:1. Second Clinical Medicine College; 2. Cardiovascular Surgery, Second Affi liated Hospital, Nanchang University, Nanchang 330006, China
Abstract:Currently, although surgical aortic valve replacement (SAVR) is still the golden standard in treatment of severe aortic stenosis according to the guideline, transcatheter aortic valve implantation (TAVI) is gradually becoming a common treatment for patients who are prohibitive or in high risk for SAVR. Recently, the valve manufacturers, including medical companies in China, are making their utmost to develop valve device, leading remarkable results achieved by TAVI. With the complications being controlled, TAVI displays promising future. It is likely that TAVI is expected to become a substitute for SAVR to treat patients with aortic stenosis or even aortic regurgitation.
Keywords:aortic stenosis  transcatheter aortic valve implantation  surgical aortic valve replacement  
点击此处可从《中南大学学报(医学版)》浏览原始摘要信息
点击此处可从《中南大学学报(医学版)》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号